Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase

Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase

Although the majority of patients with chronic myeloid leukemia (CML) enjoy an excellent prognosis tyrosine kinase inhibitor (TKI) therapy, resistance remains a significant clinical problem. Resistance can arise from mutations in the kinase domain of ABL preventing drug binding, or due to ill-define...

Full description

Bibliographic Details
Main Authors: Emmanuella Oyogoa, Lukas Streich, Philipp W. Raess, Theodore Braun
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Oncology
Subjects:
CML
tyrosine kinase inhibitors
ASXL1
RUNX1
CMML-AP
systemic inflammatory and autoimmune diseases
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1217153/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1217153/full

Similar Items